1,2,4-oxadiazole derivatives as immunomodulators
The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R 1 is the side chain of Ser, R 2 is —CO-Thr, R 3 is the side chain of Asn or Glu, and R 4 , R 5 and R 6 are each H.
1. A method for treating a cancer in a subject in need thereof, comprising:
administering to the subject a compound, wherein the compound is selected from
or a pharmaceutically acceptable salt thereof; and wherein the cancer is selected from bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, lymphoma, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, and T-cell lymphoma.
2. The method of claim 1 , wherein the cancer is non-Hodgkin's lymphoma.
3. The method of claim 1 , wherein the cancer is leukemia.
4. The method of claim 1 , wherein the cancer is lymphoma.
5. The method of claim 1 , wherein the compound is
6. The method of claim 5 , wherein the cancer is non-Hodgkin's lymphoma.
7. The method of claim 5 , wherein the cancer is leukemia.
8. The method of claim 5 , wherein the cancer is lymphoma.
9. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of
10. The method of claim 9 , wherein the cancer is non-Hodgkin's lymphoma.
11. The method of claim 9 , wherein the cancer is leukemia.
12. The method of claim 9 , wherein the cancer is lymphoma.
13. The method of claim 1 , wherein the compound is
14. The method of claim 13 , wherein the cancer is non-Hodgkin's lymphoma.
15. The method of claim 13 , wherein the cancer is leukemia.
16. The method of claim 13 , wherein the cancer is lymphoma.
17. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of
18. The method of claim 17 , wherein the cancer is non-Hodgkin's lymphoma.
19. The method of claim 17 , wherein the cancer is leukemia.
20. The method of claim 17 , wherein the cancer is lymphoma.